Transcat: HC Wainwright Raises PT to $116, Reiterates Buy Rating

Transcat: HC Wainwright Raises PT to $116, Reiterates Buy Rating

In a significant update to its investment recommendations, HC Wainwright has raised the price target for Transcat (NASDAQ:TRTC) to $116, reiterating its "Buy" rating. This move comes on the heels of the company's recent quarterly earnings report and follows a string of positive analyst actions [1].

On July 2, 2025, Transcat reported a quarterly earnings per share of $0.15, beating the consensus estimate of $0.10 by $0.05. Despite the earnings beat, the stock traded down 1.5% to $70.00, reflecting market sentiment influenced by broader economic conditions and sector-specific concerns. The company's stock has a market cap of approximately $1.2 billion and a price-to-earnings ratio of 5.4 [1].

The upgrade by HC Wainwright suggests that the analyst believes in the long-term potential of Transcat, despite recent market volatility. The firm's focus on developing innovative medical devices and its strong pipeline of products are seen as promising by the analyst. Transcat's principal asset, the Transcat Medical Device Platform, is located in the medical technology sector, which has been experiencing robust growth and demand.

Investors should continue to monitor the company's progress in its product development and clinical trials, as well as the broader market conditions that may impact the stock price. The recent analyst upgrade by HC Wainwright provides a positive outlook, but the company's performance in the coming quarters will be crucial in determining its long-term trajectory.

References:
[1] https://www.marketscreener.com/news/certain-common-shares-of-transcat-corp-are-subject-to-a-lock-up-agreement-ending-on-16-au-ce7c51dfd98bf625